You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
HUTCHMED savolitinib NDA for MET-amplified gastric cancer accepted for priority review in China
Login
Username:

Password:


Related Headlines

AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer

Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer

BioNTech completes acquisition of CureVac

BiBBInstruments reports additional US orders during targeted EndoDrill GI launch

Avacta reports tumour shrinkage and 90% disease control rate for AVA6000 in salivary gland cancer patients

Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic

RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL

Genmab completes tender offer for Merus and opens subsequent offering period

NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment

Anixa Biosciences reveals final data from Phase one clinical trial of investigational breast cancer vaccine at 2025 San Antonio Breast Cancer Symposium

Privo Technologies doses first patient in first-in-human clinical trial of PRV131

Senhwa Biosciences signs clinical supply agreement with BeOne Medicines

D3 Bio completes USD108m Series B financing round

Champions Oncology expands bioanalytical services with new technology and leadership

Poolbeg Pharma trial to feature in major CRS research programme

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025